1. TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC 2008. Time (days) 5 10 15 0 050100150200250300350400 450 Proportion of patients (%) 9.5 6.5 12.4 10.0 HR=0.79 (0.65–0.97) NNT=42 P=0.02 RRR=21% P=0.002 RRR=32% Clopidogrel Prasugrel Age-adjusted HR=0.81 (0.66-0.99)

2. TRITON TIMI-38 STEMI cohort Efficacy End Points at 15 Months Clopidogrel Prasugrel 0 2 4 6 8 10 12 14 P=0.11 P=0.02 P=0.09 P=0.02 P=0.007 P=0.03 P=0.02 Proportion of population (%) All DeathMIUTVRStent Thrombosis* CV Death/ MI CV Death/ MI/UTVR CV Death/ MI/Stroke * ARC def/probable Adapted from Montalescot et al. ESC 2008.

3. TRITON TIMI-38 STEMI cohort Stent thrombosis ARC Definite/probable HR=0.58 (0.36–0.93) NNT=83 P=0.02 RRR=42% 0100200300400 0 1 2 3 Proportion of patients (%) Time (Days) 2.4 1.2 2.8 1.6 P=0.008 RRR=51% Clopidogrel Prasugrel Age-adjusted HR=0.59 (0.37-0.96) Adapted from Montalescot et al. ESC 2008.

4. TRITON TIMI-38 STEMI cohort TIMI major non-CABG bleeding 0.5 1.0 2.0 2.5 1.5 2.1 2.4 HR=1.11 (0.70–1.77) NNH=333 Proportion of patients (%) Time (Days) P=0.65 0100200300400 0 Clopidogrel Prasugrel Age-adjusted HR=1.19 (0.75-1.89) Adapted from Montalescot et al. ESC 2008.

5. TRITON TIMI-38 STEMI cohort End point Nondiabetics, HR (95% CI) Diabetics, HR (95% CI) P for interaction CV death, nonfatal MI, or stroke* 0.86 (0.76–0.98) 0.70 (0.58–0.85) 0.09 MI 0.82 (0.72–0.95) 0.60 (0.48–0.76) 0.02 Major hemorrhage 1.43 (1.07–1.91) 1.06 (0.66–1.69) 0.29 Major or minor hemorrhage 1.32 (1.08–1.61) 1.30 (0.92–1.82) 0.93 All-cause death or nonfatal MI, stroke, or major hemorrhage 0.92 (0.82–1.03) 0.74 (0.62–0.89) 0.05 Adapted from Wiviott et al. Circulation 2008; available at: http://circ.ahajournals.org. *primary end point Hazard Ratios for Primary and Other End Points, Prasugrel vs. Clopidogrel, for Nondiabetics and Diabetics in TRITON-TIMI 38